 1. All patients with histologically or cytologically confirmed relapsed or refractory AML except acute promyelocytic leukemia; relapsed disease or refractory refractory to a non-high-dose cytarabine-containing regimen only; receiving 1st, 2nd or 3rd salvage; any cytogenetic or molecular abnormality. Patients with secondary AML after prior myelodysplasia or therapy for other cancers will be included. 